IRCT20130811014330N8已完成未知
To determine the cardiovascular effects triodithyronine (T3) in patients poisoned with aluminum phosphide (AlP)
Mashhad University of Medical Sciences,vice chancellor for research0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 85 years（—）
- 性别
- All
入选标准
- •aluminum phosphide (AlP) poisoning
- •Informed consent
排除标准
- •The patient's silver nitrate test is negative.
- •The patient has taken non-phosphoric rice tablets (herbal type).
研究者
相似试验
已完成
不适用
A study to determine the cardiovascular effects of different methods of administering the oxytocic drug SyntocinoISRCTN07452238Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)30
招募中
3 期
Evaluation of the effects of the cardioprotective diet on prevention of the incidence of cardiotoxicitycardiotoxicity in patients with breast cancer receiving Anthracycline.Malignant NeoplasmsC00-C97IRCT20131218015860N7School of Traditional Medicine, Traditional Medicine and Materia Medica Research Center,Shahid Behes60
已完成
不适用
The Cardiac Return Assist Blanket (CRAB) safely increases central venous pressure.Central venous pressureAnaesthesiology - Other anaesthesiologyACTRN12621000840886Coco Industries Pty Ltd16
进行中（未招募）
不适用
A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes MellitusType 2 diabetes patients with a recent acute coronary syndrome (ACS) eventMedDRA version: 14.1Level: PTClassification code 10007649Term: Cardiovascular disorderSystem Organ Class: 10007541 - Cardiac disordersEUCTR2009-012269-71-CZF. Hoffmann-La Roche Ltd.7,000
进行中（未招募）
1 期
Cardiovascular outcomes study to evaluate the potential of aleglitazar to reduce cardiovascular risk in patients with a recent acute coronary syndrome (ACS) event and type 2 diabetes mellitus (T2D)Type 2 diabetes patients with a recent acute coronary syndrome (ACS) eventMedDRA version: 12.0Level: LLTClassification code 10007649Term: Cardiovascular disorderEUCTR2009-012269-71-FRF. Hoffmann-La Roche Ltd.7,226